PURPOSE: Pulmonary ischemia-reperfusion is a pathological process seen in several clinical conditions, including lung transplantation, cardiopulmonary bypass, resuscitation for circulatory arrest, atherosclerosis, and pulmonary embolism. A better understanding of its molecular mechanisms is very important. METHODS: Rat left lung underwent in situ ischemia for 60 min, followed by 2 h of reperfusion. The gene expression profiles and Src protein tyrosine kinase (PTK) phosphorylation were studied over time, and PP2, an Src PTK inhibitor, was intravenously administered 10 min before lung ischemia to determine the role of Src PTK in lung injury. RESULTS: Reperfusion following ischemia significantly changed the expression of 169 genes, with Mmp8, Mmp9, S100a9, and S100a8 being the most upregulated genes. Ischemia alone only affected expression of 9 genes in the lung. However, Src PTK phosphorylation (activation) was increased in the ischemic lung, mainly on the alveolar wall. Src PTK inhibitor pretreatment decreased phosphorylation of Src PTKs, total protein tyrosine phosphorylation, and STAT3 phosphorylation. It increased phosphorylation of the p85α subunit of PI3 kinase, a signal pathway that can inhibit coagulation and inflammation. PP2 reduced leukocyte infiltration in the lung, apoptotic cell death, fibrin deposition, and severity of acute lung injury after reperfusion. Src inhibition also significantly reduced CXCL1 (GRO/KI) and CCL2 (MCP-1) chemokine levels in the serum. CONCLUSION: During pulmonary ischemia, Src PTK activation, rather than alteration in gene expression, may play a critical role in reperfusion-induced lung injury. Src PTK inhibition presents a new prophylactic treatment for pulmonary ischemia-reperfusion-induced acute lung injury.
PURPOSE:Pulmonary ischemia-reperfusion is a pathological process seen in several clinical conditions, including lung transplantation, cardiopulmonary bypass, resuscitation for circulatory arrest, atherosclerosis, and pulmonary embolism. A better understanding of its molecular mechanisms is very important. METHODS:Rat left lung underwent in situ ischemia for 60 min, followed by 2 h of reperfusion. The gene expression profiles and Src protein tyrosine kinase (PTK) phosphorylation were studied over time, and PP2, an Src PTK inhibitor, was intravenously administered 10 min before lung ischemia to determine the role of Src PTK in lung injury. RESULTS: Reperfusion following ischemia significantly changed the expression of 169 genes, with Mmp8, Mmp9, S100a9, and S100a8 being the most upregulated genes. Ischemia alone only affected expression of 9 genes in the lung. However, Src PTK phosphorylation (activation) was increased in the ischemic lung, mainly on the alveolar wall. Src PTK inhibitor pretreatment decreased phosphorylation of Src PTKs, total protein tyrosine phosphorylation, and STAT3 phosphorylation. It increased phosphorylation of the p85α subunit of PI3 kinase, a signal pathway that can inhibit coagulation and inflammation. PP2 reduced leukocyte infiltration in the lung, apoptotic cell death, fibrin deposition, and severity of acute lung injury after reperfusion. Src inhibition also significantly reduced CXCL1 (GRO/KI) and CCL2 (MCP-1) chemokine levels in the serum. CONCLUSION: During pulmonary ischemia, Src PTK activation, rather than alteration in gene expression, may play a critical role in reperfusion-induced lung injury. Src PTK inhibition presents a new prophylactic treatment for pulmonary ischemia-reperfusion-induced acute lung injury.
Authors: Mariano Severgnini; Satoe Takahashi; Powen Tu; George Perides; Robert J Homer; Jhung W Jhung; Deepa Bhavsar; Brent H Cochran; Amy R Simon Journal: Am J Respir Crit Care Med Date: 2005-01-21 Impact factor: 21.405
Authors: Willem A den Hengst; Jan F Gielis; Judy Y Lin; Paul E Van Schil; Leon J De Windt; An L Moens Journal: Am J Physiol Heart Circ Physiol Date: 2010-09-10 Impact factor: 4.733
Authors: R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove Journal: Oncogene Date: 2001-05-03 Impact factor: 9.867
Authors: Marco Mura; Matthew Binnie; Bing Han; Chengjin Li; Cristiano F Andrade; Atsushi Shiozaki; Yu Zhang; Napoleone Ferrara; David Hwang; Thomas K Waddell; Shaf Keshavjee; Mingyao Liu Journal: Am J Pathol Date: 2010-02-18 Impact factor: 4.307
Authors: Rachel G Khadaroo; Ruijuan He; Jean Parodo; Kinga A Powers; John C Marshall; Andras Kapus; Ori D Rotstein Journal: Surgery Date: 2004-08 Impact factor: 3.982
Authors: Mark D Stegall; Walter D Park; Dean Y Kim; Marco Covarrubias; Anis Khair; Walter K Kremers Journal: Transplantation Date: 2002-10-15 Impact factor: 4.939
Authors: M Anraku; M J Cameron; T K Waddell; M Liu; T Arenovich; M Sato; M Cypel; A F Pierre; M de Perrot; D J Kelvin; S Keshavjee Journal: Am J Transplant Date: 2008-08-22 Impact factor: 8.086
Authors: Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung Journal: Ann N Y Acad Sci Date: 2009-08 Impact factor: 5.691
Authors: Leif D Nelin; Hilary A White; Yi Jin; Jennifer K Trittmann; Bernadette Chen; Yusen Liu Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-02-26 Impact factor: 5.464
Authors: Marios Tomazou; Marilena M Bourdakou; George Minadakis; Margarita Zachariou; Anastasis Oulas; Evangelos Karatzas; Eleni M Loizidou; Andrea C Kakouri; Christiana C Christodoulou; Kyriaki Savva; Maria Zanti; Anna Onisiforou; Sotiroula Afxenti; Jan Richter; Christina G Christodoulou; Theodoros Kyprianou; George Kolios; Nikolas Dietis; George M Spyrou Journal: Brief Bioinform Date: 2021-11-05 Impact factor: 11.622